Anxiety disorders decline in prevalence with advancing age but remain more common than depressive disorders. They are often of late-onset and there is frequent comorbidity with depressive disorders and physical illness. While anxiety disorders in older people are likely to respond to the same non-pharmacological interventions that have been shown to work in younger people, there is currently little formal evidence of this. Although there is some evidence that the non-benzodiazepine anxiolytic medication, buspirone, is effective against late life anxiety symptoms, clinical trials in older people with rigorously diagnosed anxiety disorders are needed. An anxiety scale with demonstrated reliability and validity in older people is needed for screening for pathological anxiety and for measuring change in older patients undergoing treatment for anxiety disorders.
Introduction
The anxiety disorders are generally considered to include the following conditions: panic disorder, agoraphobia, social phobia, simple phobia, generalised anxiety disorder, posttraumatic stress disorder and obsessive-compulsive disorder. Anxiety disorders in older people have been less well studied than depression and dementia. This probably reflects the observation that older people most commonly present to clinical services with depression and dementia. It may also indicate that the level of disability associated with the anxiety disorders is not always as great as the level of disability associated with the other disorders. The rapidly changing diagnostic criteria for some of the anxiety disorders, particularly generalised anxiety disorder, has also proved challenging to researchers. In particular, the hierarchical nature of the DSM-III diagnostic rules has meant that anxiety disorders could not be diagnosed in the presence of other psychiatric disorders such as depression or dementia.
Epidemiology of anxiety in later life

Prevalence of anxiety symptoms in later life
Several early community surveys of anxiety symptoms that included older people were reported. [1] [2] [3] Two of these surveys 1, 3 found that older people reported more anxiety symptoms than younger people, whereas the other survey 2 found that approximately 10% of the population at any age had clinically significant anxiety symptoms. More recently, Himmelfarb & Murrell 4 reported findings from a survey of middle aged and older people. These authors administered the trait half of the State Trait Anxiety Inventory (STAI) 5 to 1338 females and 713 males aged 55 years and over living in the U.S. state of Kentucky. Anxiety varied inversely with education and socio-economic status. Although there was a complex relationship between anxiety and age, the general tendency was for anxiety to increase with advancing age. Overall, 17% of males and 22% of females reported levels of anxiety symptoms thought to warrant treatment.
Against this background, Henderson et al 6 surveyed a general population sample of 2725 people aged between 18 and 79 years living in Australia using two inventories of depressive and anxiety symptoms and found that the prevalence of both declined with advancing age. They noted that some risk factors for depression and anxiety, including neuroticism and adverse life events, also declined with advancing age. Henderson et al 6 noted that unless their sample was affected by a participation bias their findings supported the view that depressive and anxiety symptoms actually do decline with increasing age.
In summary, although historically there has been divided opinion about whether anxiety symptoms decline in later life more recent work supports this conclusion.
Overall prevalence of anxiety disorders in older people
The overall prevalence of the anxiety disorders in people aged 65 years and over has been estimated in several large-scale surveys, with more recent studies producing prevalence estimates varying from 0.9% to 15.0% (Table) . Much of this variation is likely to be due to the use of different diagnostic instruments and different diagnostic algorithms. In the Epidemiologic Catchment Area (ECA) study, subjects were interviewed using the Diagnostic Interview Schedule (DIS), 7 which generated DSM-III anxiety diagnoses other than Generalised Anxiety Disorder (GAD). The one-month prevalence of any anxiety disorder (other than GAD) for subjects aged 65 years and over from five U.S. sites (N=5,702) was found to be 6.8%. 8 The New Haven, Connecticut, site of the ECA study over sampled older people, with the final study sample including 2,588 community residing individuals aged 65 years or over. 9 At this site, the six-month prevalence of any anxiety disorder (including somatization but not GAD) was 4.6%. In a similar study conducted in Edmonton, Canada 10 358 community residing older people were interviewed with the DIS. The six-month prevalence rate of any anxiety disorder (including somatization but not GAD) was found to be 3.5%. Copeland et al 11 assessed 1,070 elderly Liverpool, England, general practitioner patients using the Geriatric Mental State schedule and its associated diagnostic algorithm (GMS/AGECAT). They found only 26 subjects (2.4%) who met criteria for neurosis caseness, including 10 subjects (0.9%) who met criteria for anxiety neurosis caseness. The same group found similar levels of caseness in London but lower levels of caseness in New York. 12 Banerjee 13 surveyed 169 elderly residents of Lewisham, London, who were receiving home care services, using the GMS/AGECAT system. Four residents (2.4%) were categorized as cases of anxiety disorder and 24 (14.2%) as sub cases. Manela et al 14 surveyed 694 residents of the deprived London suburb of Islington using the Anxiety Disorder Scale (ADS) 15 and found the prevalence of anxiety disorders (including generalised anxiety) to be 15.0%. A recent Australian survey 16 found the overall prevalence of anxiety disorders in people aged 65 years and over to be 4.5%. Studies that employed less rigorous diagnostic approaches have also been reported. 17, 18 These latter studies generated estimates of caseness much greater than those generated by the more rigorous studies already reviewed.
In both the ECA and Australian surveys, the prevalence of anxiety disorders in older people was significantly lower than that in young and middle age people. This observation has lead to concern that the measures used to diagnose anxiety disorders in epidemiological surveys may be systematically biased against making these diagnoses in older people. Concern has also arisen that anxiety disorders may be associated with excess mortality among young and middle age persons contributing to the observed lower prevalence of anxiety disorders in older people. Some commentators have been concerned also that many older people with anxiety disorders may not agree to participate in community surveys or may be too medically ill to do so. Jorm 19 reviewed studies that had examined the prevalence of anxiety and depressive disorders and symptoms across the lifespan. He concluded that neither excess mortality nor exclusion of institutionalised patients from community surveys could explain the lower prevalence of depressive and anxiety symptoms and disorders in older people.
Prevalence of specific anxiety disorders in older people
The prevalence of individual anxiety disorders in later life has also been studied and will now be briefly summarised. It should be noted, however, that because of the relatively small samples recruited to studies of anxiety disorders in older people, the uncertainty associated with estimates of the prevalence of individual anxiety disorders is likely to be considerably greater that the uncertainty associated with estimates of the prevalence of the anxiety disorders as a group. Estimates of the prevalence of generalised anxiety disorder in older people have varied between 0.7 and 7.1%, although the ECA study did not report prevalence data for this condition. 11, 12, 14, 15 One problem with being confident of the prevalence of generalised anxiety disorder is that the diagnostic criteria for this condition have changed considerably over the past twenty years. Estimates of the prevalence of phobic disorders in older people have varied between 0.0 and 12.0% with more recent estimates tending to support the higher figure. 14, 15, 20 Much of this variation is due to the use of differing diagnostic criteria including the presence or absence of hierarchical diagnostic rules. The limited available evidence suggests that most cases of simple phobia in older people have arisen early in life whereas most cases of agoraphobia have arisen late in life. Agoraphobia in older people is not commonly associated with panic disorder but rather with physical illness or adverse life events. There is general consensus that panic disorder is the least common anxiety disorder in later life with prevalence estimates varying between 0.0 and 0.3%. 8, 14, 15, 21 Most, if not all, cases of panic disorder among older people occur in women. Obsessive-compulsive disorder is generally considered to be uncommon among community residing older people with estimates of its prevalence varying between 0.0 and 1.5%. 20, 22, 23 It may arise for the first time in later life but generally arises before the age of 65 years. Whilst surveys of Holocaust and POW camp survivors have found high rates of post-traumatic stress disorder (PTSD), the prevalence of the condition in unselected community samples of older people is uncertain. 20 
Incidence of anxiety disorders in older people
Little is known about the incidence of anxiety disorders in later life. In addition, it is not clear what proportion of anxiety disorders are of early and late onset. Larkin et al, 24 in a three-year follow-up of the Liverpool sample, found the incidence of neurotic disorders among older people to be 4.4/1000 per year. In the Guy's/Age Concern survey, Lindesay 25 found that in one third of cases phobic disorders had had their onset after the age of 65 years. However, the majority of cases of agoraphobia were of late onset and followed serious physical illness or injury.
Anxiety disorders in special populations of older people
Some studies have estimated the prevalence of anxiety disorders in special populations of older people. Juninger et al 26 found the prevalence of SCID/DSM-III-R anxiety disorders in 100 Baton Rouge, Louisiana, nursing home residents to be 20%. Diagnostic criteria for GAD were met by 6% of residents. The prevalence of anxiety disorders was assessed in the residents of five Sydney, Australia, nursing homes using a questionnaire. 27 Only residents with MMSE scores of 18 or greater were included in the study. Twelve of 107 (11.2%) nursing home residents reported symptoms of generalised anxiety. However, a subsequent psychiatric interview using DSM-III-R criteria found that only 3 of the 12 (2.8% of the total) met diagnostic criteria for GAD. A consecutive series of stroke patients (N=309) admitted to hospital in Baltimore, Maryland, was assessed with a modified version of the Present State Examination. 28 DSM-II-R criteria for GAD were present in 25% of patients. A population-based prospective study of 80 Swedish stroke patients with a mean age of 73 years 29 found the prevalence of DSM-III-R Generalised Anxiety Disorder to be 28%. Teri et al 30 studied the prevalence of anxiety and other symptoms in 523 community-residing patients with Alzheimer's disease using a 21-item checklist. Seventy percent of subjects had one or more anxiety symptoms and 57% had two or more anxiety symptoms. However, anxiety disorders were not assessed.
Psychiatric comorbidity of anxiety disorders in older people
There is evidence of substantial comorbidity between different specific anxiety disorders and between anxiety disorders and depressive disorders in people of all ages. However, among older patients with anxiety disorders there is uncertainty about which disorder is more likely to have developed first. Mulsant et al 31 studied the prevalence of comorbid anxiety disorder in 336 older patients with Major Depressive Disorder. Among 177 outpatients, 15 (8.5%) met diagnostic criteria for a lifetime comorbid anxiety disorder. However, no inpatients met diagnostic criteria for a current anxiety disorder. Among 159 outpatients, 9 (5.7%) met diagnostic criteria for a current anxiety disorder and 13 (8.2%) met diagnostic criteria for a lifetime anxiety disorder. In the Longitudinal Aging Study Amsterdam, Beekman et al 32 studied 659 community-based subjects aged between 55 and 85 years with the Center for Epidemiologic Studies Depression Scale (CES-D) 33 and the Diagnostic Interview Schedule (DIS). They found that 111 subjects (16.8%) met diagnostic criteria for an anxiety disorder, mainly generalised anxiety disorder and social phobia. Of those with an anxiety disorder, 26.1% also met diagnostic criteria for major depressive disorder and of those with major depressive disorder, 47.5% also met diagnostic criteria for an anxiety disorder.
Measurement of anxiety symptoms in later life
A measure of dimensional anxiety specifically designed for use in older people is urgently needed. Such a measure might be used in a variety of settings to screen for patients likely to be suffering from anxiety disorders and to measure change over time in patients having treatment for an anxiety disorder. Although several such measures have been assessed, all have been found wanting. Several of these measures are now reviewed.
Among clinician-rated measures, only the Hamilton Anxiety Rating Scale (HAM-A) 34 has been examined in older subjects with rigorously diagnosed anxiety disorder. Beck & Steer 35 found that the HAM-A discriminated well between older subjects with Generalised Anxiety Disorder (GAD) and normal control subjects. However, the use of the HAM-A has been called into question in older people because of its heavy reliance upon somatic items.
Among self-report measures, the Spielberger State-Trait Anxiety Inventory (STAI) 5 was used in some early studies of older people, 4, 36 although these studies did not report specific diagnostic data. More recent evidence suggests that the state component of the STAI does not adequately distinguish between older patients with current anxiety disorders and those without such disorders. 37 The Beck Anxiety Inventory (BAI) 35 has been used also in several studies. [37] [38] [39] These studies provide some evidence that the BAI may be able to distinguish between older people with and without clinically significant anxiety. However, the BAI also relies heavily upon somatic items, making its use in medically ill older people potentially problematic. The Hospital Anxiety and Depression Scale (HADS) 40 has been found to lack sensitivity and specificity as a screening instrument for anxiety and depressive disorders in older people diagnosed using the Geriatric Mental State schedule (GMS). 41 A four-item version of the 11-item Anxiety Disorder Scale (ADS) called the FEAR 42 has been proposed as a rapid screening measure for non-hierarchical clinical ICD-10 diagnoses of generalised anxiety disorder in older people. However, it seems that the FEAR has not yet been tested independently of the ADS. A French language version of Goldberg's 18-item depression and anxiety inventory 43 was used to detect depression and anxiety disorders in hospitalised elderly patients. 44 Whilst the inventory demonstrated satisfactory sensitivity, the subscales lacked specificity for each type of disorder.
A measure that was specifically developed to measure anxiety in older people has recently been described. The Short Anxiety Screening Test (SAST) 45 is a 10-item selfreport instrument with a four-point response scale generating scores between 10 and 40. Four of the 10 items assess somatic symptoms (pain, palpitations, sleep, dizziness), potentially limiting the ability of the scale to distinguish between anxiety and somatic symptoms. On the basis of pilot data, subjects scoring greater than 23 on the SAST were said to have a "diagnosis of anxiety". In the only published study using the instrument, 45 the SAST was administered to 150 geriatric medical patients with a mean age of 82 years. DSM-IV diagnoses were established using a modified version of the Anxiety Disorders Interview Schedule (ADIS-IV). 46 SAST test-retest reliability was good (r p =0.73; p<0.0001). The SAST was found to have sensitivity of 75.4%, specificity of 78.7%, positive predictive value of 70.8% and negative predictive value of 82.4% against modified ADIS-IV interviews by a psychiatrist. However, the performance of the SAST in relation to individual DSM-IV anxiety disorders was not disclosed. Nor is it clear whether the SAST is sensitive to change when anxiety disorders are treated. It is unclear whether the SAST will have clinical utility in older people seen in mental health settings.
Measures of worry, 47, 48 obsessional thinking, 49 phobias, 50 anxiety about ageing, 51 retirement anxiety 52 and death anxiety 53 have also been studied in older subjects. However, as these measures are all rather narrowly focussed, they will not be discussed any further here.
The ideal measure of dimensional anxiety in older people is yet to be developed. It is likely that such a measure would distinguish well between older people with and without anxiety disorders, particularly GAD, distinguish anxiety disorders from depressive disorders, and distinguish medically ill people with an anxiety disorder from medically ill people without an anxiety disorder. Properties of the Geriatric Depression Scale (GDS) 54 such as a dichotomous response scale, the absence of somatic items and careful attention to the wording of scale items might be important features of such a new scale. However, there is a need for more normative data for existing anxiety measures from older people of both genders 55 and different cultures. There is also a need for normative data that come from both the 'young' old and the 'old' old.
Clinical features
Very little published work has looked systematically at the similarities and differences between the clinical features of anxiety disorders occurring in younger and older people. Schuab & Linden 56 found that the symptomatology of anxiety disorders in later life was similar to that in younger people. Sheikh et al 57 surveyed 520 adults with panic attacks, of whom 445 were younger than 55 years and 75 were aged 55 years or older. Of the 75 older subjects, 57 (76%) had their first panic attack before the age of 55 years and 18 (24%) had their first panic attack after the age of 55 years. Those with late-onset panic attacks reported fewer symptoms during their panic attacks and were generally less avoidant.
A aetiology of anxiety disorders in later life
The aetiology of anxiety disorders in later life is, for the most part, obscure. However, as previously noted, Lindesay 25 found that most late life cases of agoraphobia were of recent onset and came on following serious illness or injury. The apparently high prevalence of anxiety disorders in patients with dementia or following stroke certainly suggests organic factors in at least some cases. However, the overall decline in the prevalence of anxiety disorders with advancing age suggests the presence of one or more general protective factors associated with ageing. One possible biological protective factor is a reduction in the responsiveness of the central noradrenergic neurotransmitter system together with relatively preserved inhibitory gamma amino butyric acid (GABA) activity in the central nervous system. From the psychological perspective, it may be that older people have been inoculated against the anxiety generating effects of adverse life events by repeated exposure earlier in life. Or perhaps the declining prevalence of both neuroticism and adverse life events in later life, together with the apparent increase in available social support, are protective against anxiety disorders as well as depressive disorders. 6 
Treatment of anxiety disorders
Non-pharmacological treatment
Several studies have investigated the non-pharmacological treatment of anxiety symptoms in older people. However, there appears to be only one study of non-pharmacological treatment of a defined anxiety disorder. 58 In a study of 48 relatively young (mean age 68 years) older people with Generalised Anxiety Disorder, subjects were randomly assigned to either cognitive behaviour therapy (CBT) or to supportive psychotherapy (SP). 59 Each treatment was conducted in a small-group setting over 14 weeks. Thirty-one patients (65%) completed treatment. In a responder analysis, 28% of subjects randomised to CBT and 54% of subjects randomised to SP were found to have responded to treatment. Although there is no obvious a priori reason why older people with anxiety disorders should not respond to treatment with similar non-pharmacological interventions to those demonstrated to be effective in younger people, it is likely that modified treatment approaches will be needed. For instance, some of the components of CBT require modification for use in older people. 60 
Pharmacological treatment
There appear to be no studies of pharmacological interventions for rigorously diagnosed anxiety disorders in older people. However, studies of buspirone 61 and alpidem 62 in anxious older people have been reported. In a 4-week study, 61 40 anxious subjects with a mean age of 72 years were randomised to either placebo or buspirone 15-30 mg per day in divided doses. Mean scores on the Hamilton Rating Scale for Anxiety (HAM-A) fell from 22.9 to 6.4 in subjects assigned to buspirone and from 22.1 to 15.8 in subjects assigned to placebo (p<0.005). In clinical use, buspirone has been found to be a useful adjunct to the non-pharmacological management of anxiety in benzodiazepine naïve patients. In a 3-week study, 62 40 anxious subjects who ranged in age between 65 and 80 years were randomised to either placebo or alpidem 75-150 mg per day (most common dose 75 mg per day). On a variety of outcome measures, including the HAM-A and the STAI, alpidem was superior to placebo (p<0.01) and the anxiolytic action was evident after seven days of treatment. The authors reported no impairment of psychomotor or memory performance with this anxiolytic. However, alpidem was subsequently withdrawn from the market after several reports of hepatotoxicity, some of them fatal.
In relation to the pharmacological management of anxiety disorders in older people, the use of benzodiazepines has significant risks. These include confusion, amnesia, ataxia and falls. Thus, alternative pharmacological strategies are required. The use of newer antidepressants with proven efficacy in anxiety disorders in younger adults seems appropriate, although there is a conspicuous absence of randomised controlled trial data in older people.
Conclusions
Although anxiety symptoms remain commonplace amongst older people, the prevalence of the anxiety disorders appears to decrease with advancing age. As is the case for depressive disorders, older women remain more susceptible than older men. Anxiety disorders appear to be more prevalent among nursing home residents and older people with medical conditions such as stroke and dementia. However, little is known about the specific clinical features of anxiety disorders in older people and whether these differ from the clinical features of anxiety disorders in younger people. A suitable scale to measure generalised anxiety in older people is yet to be developed. Not much is known about the evidence-based management of anxiety disorders in older people. Very few clinical trials of pharmacological agents have been undertaken in older people with anxiety disorders. The limited available evidence derived from a single clinical trial conducted in older people with anxiety symptoms favours the use of the nonbenzodiazepine anxiolytic buspirone. Further investigation of non-pharmacological interventions is urgently needed. Thus, there are great opportunities for mental health personnel who work with older people to advance clinical knowledge in the assessment and management of anxiety disorders.
